Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ Twenty-three patients received ivosidenib ...

Mutations in isocitrate dehydrogenase (IDH) genes, an early step in the ontogeny of lower-grade gliomas, induce global epigenetic changes characterized by a hypermethylation phenotype and are critical ...

Somatic monoallelic single nucleotide variants in the genes that encode isocitrate dehydrogenase (IDH) 1 and 2 are found in a large subset of diffusely infiltrating gliomas and subsets of acute ...

Vorasidenib becomes the first targeted therapy for grade 2 isocitrate dehydrogenase (IDH)–mutant glioma to receive FDA approval. "Today's approval of Voranigo is an enormous leap forward in cancer ...

Vorasidenib is an investigational oral, selective, highly brain-penetrant dual inhibitor of IDH1/2 enzymes. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...

The FDA has approved Voranigo to treat certain patients with grade 2 astrocytoma or oligodendroglioma with select mutations, following surgery. The Food and Drug Administration (FDA) has approved ...

Mutations in the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) induce tumorigenesis due to generation of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). A hallmark of solid tumors carrying ...

NeOnc Technologies (NTHI) announced updated clinical results from its current Phase 1/2a and compassionate care studies involving a cohort of 24 ...